Transient insulin treatment optimized by continuous subcutaneous insulin infusion (CSII) is effective in rapidly reducing hyperglycemia and glucotoxicity, and leads to the restoration of insulin sensitivity in T2DM [21]. The gene discussed is INS; the disease is Hyperglycemia.